Evinova, a new global health tech business launched by AstraZeneca, aims to revolutionize the clinical trial process. The company’s goal is to reduce the time and cost of clinical trials while making the process easier for patients.
Operating as a separate business financially backed by AstraZeneca, Evinova will provide global services to CROs and pharmaceutical companies to design, run, and monitor clinical trials. The company will charge customers for access to its technology and operate on a revenue-based model.
With the creation of Evinova, AstraZeneca hopes to address the challenges and inefficiencies in the clinical trial process. By doing so, it aims to make it easier for patients to participate and improve the overall effectiveness of the trials. This new venture reflects AstraZeneca’s commitment to advancing healthcare and utilizing technology to improve drug development processes.